Ultragenyx Pharmaceutical (RARE) Net Income Growth (3y) (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) Net Income Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.16%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -3.84%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.26%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Ultragenyx Pharmaceutical 2.71 Bn 2.30 Bn 106.00 Mn -4.10%

Historic Data

Download Data
DateValue
Mar 31, 2026 -4.10%
Dec 31, 2025 7.22%
Sep 30, 2025 9.71%
Jun 30, 2025 10.09%
Mar 31, 2025 0.29%
Dec 31, 2024 -33.67%
Sep 30, 2024 -22.29%
Jun 30, 2024 -2.44%
Mar 31, 2024 -7.83%
Dec 31, 2023 -40.05%
Sep 30, 2023 -32.36%
Jun 30, 2023 -102.58%
Mar 31, 2023 -11.27%
Dec 31, 2022 -35.69%
Sep 30, 2022 -29.45%
Jun 30, 2022 -16.83%
Mar 31, 2022 -16.33%
Dec 31, 2021 79.57%
Sep 30, 2021 5.79%
Jun 30, 2021 -32.42%